021-51111890
购物车（）
sales@molnova.cn
Thalidomide-O-amido-PEG2-C2-NH2 hydrochloride
CAS No. 2376990-30-4
Thalidomide-O-amido-PEG2-C2-NH2 hydrochloride ( —— )
产品货号. M27021 CAS No. 2376990-30-4
Thalidomide-O-amido-PEG2-C2-NH2 hydrochloride incorporates an E3 ligase ligand and a linker.
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 5MG | ￥567 | 有现货 |
|
| 10MG | ￥794 | 有现货 |
|
| 25MG | ￥1393 | 有现货 |
|
| 50MG | ￥2373 | 有现货 |
|
| 100MG | ￥3993 | 有现货 |
|
| 200MG | 获取报价 | 有现货 |
|
| 500MG | 获取报价 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称Thalidomide-O-amido-PEG2-C2-NH2 hydrochloride
-
注意事项本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断
-
产品简述Thalidomide-O-amido-PEG2-C2-NH2 hydrochloride incorporates an E3 ligase ligand and a linker.
-
产品描述Thalidomide-O-amido-PEG2-C2-NH2 hydrochloride incorporates an E3 ligase ligand and a linker. Thalidomide-O-amido-PEG2-C2-NH2 hydrochloride can be used as an immunomodulator for the treatment of cancer.(In Vitro):PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins. PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein.
-
同义词——
-
通路Others
-
靶点Other Targets
-
受体——
-
研究领域——
-
适应症——
化学信息
-
CAS Number2376990-30-4
-
分子量498.9
-
分子式C21H27ClN4O8
-
纯度>98% (HPLC)
-
溶解度——
-
SMILESCl.NCCOCCOCCNC(=O)COc1cccc2C(=O)N(C3CCC(=O)NC3=O)C(=O)c12
-
化学全称——
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1.Uemura M, et al. An in vivo highly antitumor-active tetrazolato-bridged dinuclear platinum(II) complex largely circumvents in vitro cisplatin resistance: two linkage isomers yield the same product upon reaction with 9-ethylguanine but exhibit different cytotoxic profiles. Metallomics. 2012 Jul;4(7):686-92.
产品手册
关联产品
-
Ureidosuccinic acid
Ureidosuccinic acid is an intermediary product in pyrimidine biosynthesis.
-
2,5-Dimethyl-3(2H)-f...
2,5-Dimethyl-3(2H)-furanone is a non-genotoxic flavoring substance.
-
PHA-767491
PHA-767491 is a potent ATP-competitive dual Cdc7/CDK9 inhibitor with IC50 of 10 nM and 34 nM, respectively.
